A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome

References

• Leschziner G, Gringras P. Restless legs syndrome. BMJ 2012;344:e3056
   PubMed Web of Science ®Google Scholar
• Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-42
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19
   PubMed Web of Science ®Google Scholar
• Kohnen R, Stiasny-Kolster K, Oertel WH, et al. Severity rating of restless legs syndrome: validation of the RLS-6 scales. Sleep 2004;27(Suppl 1):A304
   Google Scholar
• 028 CG I. Clinical global impressions. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:217-22
   Google Scholar
• Hening WA, Allen R, Chokroverty S, Earley C, eds. Restless Legs Syndrome. Philadelphia: Elsevier/Saunders, 2009
   Google Scholar
• Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-46
   PubMed Web of Science ®Google Scholar
• Kushida C, Martin M, Nikam P, et al. Burden of restless legs syndrome on health-related quality of life. Qual Life Res 2007;16:617-24
   PubMed Web of Science ®Google Scholar
• Talati R, Phung OJ, Mather J, et al. Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome. Ann Pharmacother 2009;43:813-21
   PubMed Web of Science ®Google Scholar
• Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011;26:114-20
   PubMed Web of Science ®Google Scholar
• Dodel R, Happe S, Peglau I, et al. Health economic burden of patients with restless legs syndrome in a German ambulatory setting. Pharmacoeconomics 2010;28:381-93
   PubMed Web of Science ®Google Scholar
• Hornyak M. Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management. CNS Drugs 2010;24:89-98
   PubMed Web of Science ®Google Scholar
• Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for the treatment of restless legs syndrome. Cochrane Database Syst Rev 2011;(3):CD006009
   Google Scholar
• Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol 2011;11:117
   PubMed Web of Science ®Google Scholar
• Bassetti CL, Bornatico F, Fuhr P, et al. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly 2011;141:w13274
   PubMed Web of Science ®Google Scholar
• Allen R, Becker P, Patrick J, et al. Comparison of pregabalin, pramipexole and placebo effects on symptoms, limb movements and sleep maintenance in restless legs syndrome (Willis–Ekbom disease). Mov Disord 2012;27(Suppl 1):Abstract 1215
   Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Higgins J, Green S, eds. www.cochrane-handbook.org: The Cochrane Collaboration 2011
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Treatment for Restless Legs Syndrome. Comparative Effectiveness Review. AHRQ Publication No. 86. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ): 2012; 12(13)-EHC147-EF
   Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17
   PubMed Web of Science ®Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-55
   Web of Science ®Google Scholar
• Adler CH, Hauser RA, Sethi K, et al. Ropinirole for restless legs syndrome: a placebo-controlled crossover trial. Neurology 2004;62:1405-7
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011;26:2065-72
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Hogl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis–Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 2012;27:277-83
   PubMed Web of Science ®Google Scholar
• Kushida CA, Geyer J, Tolson JM, et al. Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome. Clin Neuropharmacol 2008;31:281-6
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hirata K, Kuroda K, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med 2010;11:11-16
   PubMed Web of Science ®Google Scholar
• Ma JF, Wan Q, Hu XY, et al. Efficacy and safety of pramipexole in Chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial. Sleep Med 2012;13:58-63
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med 2010;11:848-56
   PubMed Web of Science ®Google Scholar
• Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology 2009;72:439-46
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9
   PubMed Web of Science ®Google Scholar
• Oertel WH, Beneš H, García-Borreguero D, et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008;9:228-39
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord 2010;25:1675-83
   PubMed Web of Science ®Google Scholar
• Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-19
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008;7:595-604
   PubMed Web of Science ®Google Scholar
• Benes H, Mattern W, Peglau I, et al. Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study. J Neurol 2011;258:1046-54
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-7
   PubMed Web of Science ®Google Scholar
• Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-14
   PubMed Web of Science ®Google Scholar
• Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-23
   PubMed Web of Science ®Google Scholar
• Montagna P, Hornyak M, Ulfberg J, et al. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood. Sleep Med 2011;12:34-40
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial. Sleep Med 2008;9:874-81
   PubMed Web of Science ®Google Scholar
• Hogl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med 2011;12:351-60
   PubMed Web of Science ®Google Scholar